Eli Lilly (LLY 1.15%) and Novo Nordisk (NVO 0.14%) are two phenomenal growth stocks that investors probably can't go wrong ...

Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the future.

AON, a health insurance consultant, and Murphy Administration officials announced on Wednesday that premiums in the State ...

UBS has reiterated its Buy rating and $1,050 price target on LLY stock, highlighting the company’s growing dominance in the ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...

Linda Yaccarino, CEO of Elon Musk-owned social platform X, said on Wednesday she would step down from the top role in a ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Touro University Nevada is asking for volunteers to take part in a study on the long-term effects of injectable weight-loss or diabetic medication.

Novo Nordisk will lose its patent protection on its branded semaglutide drugs Ozempic and Wegovy in Canada after not paying a ...

S&P 500, Microsoft Corporation, JPMorgan Chase & Co, Eli Lilly and Company. Read 's Market Analysis on Investing.com ...

Ireland has long been a global pharmaceutical powerhouse, hosting more than 90 pharmaceutical companies and employing around ...